After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the arrival of Quentis Therapeutics, a cancer immunotherapy startup born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. The company makes its debut today with a $48 million Series A round.
Quentis has been incubating for a few years within Highline Therapeutics, the New York biotech creator Versant Ventures formed in late 2015. Versant is one of the venture firms to… Read more »
UNDERWRITERS AND PARTNERS